Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

NCT02910700 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Malignant Neoplasm in the Brain
Metastatic Melanoma
Stage III Cutaneous Melanoma AJCC v7
Stage IIIA Cutaneous Melanoma AJCC v7
Stage IIIB Cutaneous Melanoma AJCC v7
Stage IIIC Cutaneous Melanoma AJCC v7
Stage IV Cutaneous Melanoma AJCC v6 and v7
Unresectable Melanoma

Interventions

DRUG: Binimetinib
DRUG: Dabrafenib
DRUG: Encorafenib
OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Nivolumab
OTHER: Pharmacological Study
DRUG: Trametinib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]